Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023
SPAC Mergers Still A Go-Public Alternative For Some
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
